[Skip to Content]
[Skip to Content Landing]
Article
August 1984

l-Deprenyl in Atypical Depressives

Author Affiliations

From the New York State Psychiatric Institute, New York; and the Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York (Drs Quitkin, Liebowitz, Stewart, McGrath, Harrison, and Rabkin and Mr Markowitz).

Arch Gen Psychiatry. 1984;41(8):777-781. doi:10.1001/archpsyc.1984.01790190051006
Abstract

• We investigated the antidepressant efficacy of l-deprenyl (selegiline), a selective monoamine oxidase B inhibitor (MAOI), in a six-week open trial of 17 patients with atypical depression. Such patients have previously been shown to benefit from nonselective MAOIs such as phenelzine sulfate. Ten patients (59%) responded to l-deprenyl, but nine required dosages above the 10 to 20 mg/day used in previous investigations. l-Deprenyl was superior to six weeks of placebo administered to diagnostically similar patients in a separate double-blind study. In contrast with previous findings with phenelzine, responders to l-deprenyl differed from nonresponders by having lower baseline anxiety ratings. Even at high dosages, there appeared to be fewer side effects with l-deprenyl than with nonselective MAOIs.

×